Sanofi raised its forecasts for sales and profit this year for a second straight quarter on rising demand for its top-selling skin and asthma drug Dupixent
Sandoz said Europe’s medicines regulator is proposing to pull amoxicillin from its list of critical medicines, a potential death blow to the last European factory to make the antibiotic from scratch